Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.51 |
| ▸ | REN | P00797 | 7/20 | 0.47 |
| ▸ | CTSD | P07339 | 2/20 | 0.46 |
| ▸ | CTSE | P14091 | 2/20 | 0.46 |
| ▸ | PGC | P20142 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222704 | 1.00 | GBA1 (0.51) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL8225983 | 0.94 | GBA1 (0.49) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL3910981 | 0.94 | GBA1 (0.49) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL3911234 | 0.83 | CARM1 (0.40) | GBA1RENCTSDKMT2A | |
| SCHEMBL3910632 | 0.80 | GBA1 (0.54) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL8223739 | 0.80 | GBA1 (0.54) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL3919455 | 0.79 | GBA1 (0.54) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL8223341 | 0.79 | GBA1 (0.54) | GBA1RENCTSDCTSEPGC | |
| SCHEMBL8223793 | 0.79 | KDM1A (0.35) | GBA1REN | |
| SCHEMBL3914249 | 0.79 | KDM1A (0.35) | GBA1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | claimed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | claimed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | claimed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | GBA1 305/4885REN 757/4885CTSD 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.